| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23a4e0c875bf1ac2b8a3b76517de6c7d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-78
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-7095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16C20-64 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-497
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16C20-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6812
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-582
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B15-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57434
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16C20-50 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16C20-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B15-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16C20-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-497 |
| filingDate |
2019-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8dcc0e4aab94a318a039ce78b7efa07d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28a5b87723e73a1f989c90d8bc7a34ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a61db2565841abadfb730d6207630e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_12a85c490b7cc57f872f93e8f46e6d1e |
| publicationDate |
2020-02-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2020064334-A1 |
| titleOfInvention |
Dock Derived Compound against Laminin Receptor (37 LR) and Uses thereof |
| abstract |
An in silico screening method generated compounds that are against laminin receptor 37LR and their anti-cancer functions in prostate cancer cell lines are disclosed herein. A group of derivatives based on the hit compound from the in silico screening are synthesized and tested with improved IC 50 value that can have relevant clinical use for prostate cancer or osteoarthritis. |
| priorityDate |
2017-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |